The body of research supporting efficacy of Sabinsa’s branded ingredients continues to grow with a recent clinical paper reporting on the use of the company’s Curcumin C3 Complex^® and BioPerine^®, and taurine on hepatocellular carcinoma (HCC) patients: A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study published in the Journal of Gastrointestional Oncology.

Read more ...

Sabinsa’s Curcumin C3 Complex^® in combination with BioPerine^® (CBP) has an inhibitory effect on malignant mesothelioma cells, according to an in vitro and in vivo study published in Journal of Experimental and Clinical Cancer Research.

Read more ...

Sabinsa continues its global expansion with the opening of a warehousing, sales and distribution office in Poland and bringing on staff to serve customers in the growing East European, Eastern Block as well as CIS countries.

Read more ...

Sabinsa’s four Sami Labs manufacturing sites in India were recently audited by the licensed Certification Body, Bureau Veritas Certification Holding SAS – UK branch, and achieved Foundation Food Safety System Certification 22000 (FSSC 22000). FSSC 22000 replaces the previous ISO 22000: 2005 - FSMS (Food Safety Management System) achieved by these Sami facilities till 2018.

Read more ...

Sabinsa’s Curcumin C3 Complex^® has been studied as an adjuvant therapy with several cancer drugs in the past, and the body of science continues to grow with the recent publication of more positive research.

Read more ...

Patented Turmeric Extract Deemed Safe for Use in Foods and Beverages

After a comprehensive review of safety and toxicology data by an independent panel of scientists of international repute convened by Soni & Associates Inc., Sabinsa’s patented color-free Curcumin C3 Reduct^® tetrahydrocurcuminoids, a metabolite of curcumin, has been found to meet criteria as Generally Recognized As Safe (GRAS) as per FDA’s scientific procedures.

Read more ...

Sabinsa Achieves USP GMP Audited Status for Three Additional Sites

Three additional Sami-Sabinsa Group Manufacturing units have been audited by the United States Pharmacopeia (USP) and received GMP compliance certificates for the Kunigal unit and the Dobaspet unit, both in Bengaluru, India, and the Hyderabad unit in Telangana state, India. The company’s Nelamangala site in Bengaluru received a USP GMP certificate earlier this year. All four sites are certified Halal by The Islamic Food and Nutrition Council of America (IFANCA) and OK Kosher, with the Kunigal and Hyderabad units NSF-GMP certified as well.

Read more ...

Sabinsa’s Curcumin C3 Complex^® Identified as the Most Studied

A retrospective analysis of curcumin research presented a comprehensive look at the vast body of science on the popular extract of turmeric. Curcumin: Total-Scale Analysis of the Scientific Literature by Dr. Atanas G. Atanasov et al, a bibliometric review of literature on curcumin published in the April 2019 edition of the journal, Molecules (2019, 24, 1393), discussed investigations into a range of clinical indications, including Alzheimer’s disease, psoriasis vulgaris, obesity, oral lichen planus, osteoarthritis, inflammation associated with metabolic syndrome, and radiation dermatitis as well as for modulation of human gut microbiome.

Read more ...

Sabinsa Staff Available at Booth # 317

Sabinsa will feature two new patent-protected branded ingredients at New York Society of Cosmetic Chemists (NYSCC) Suppliers’ Day tradeshow May 7 – 8, 2019, at the Jacob K. Javits Convention Center in New York City. This important event attracts science and chemistry research management and staff, purchasing agents, and top management representing major cosmetic giants as well as small and start-up companies.

Read more ...

Grant Aids Sami Labs to Test Plant Species and Evaluate Commercial Viability in a Sustainable Manner

The Department of Scientific and Industrial Research (DSIR), under the Government of India’s Ministry of Science and Technology has sanctioned funding to Sabinsa’s parent company Sami Labs for research on “Development and standardization of manufacturing processes for large scale production of valuable secondary metabolites from callus-derived cells of vascular cambial explants of selected woody plant species.”

Read more ...